(Q37573653)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19658185%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

review article

1 reference

title

Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19658185%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19658185%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Suresh S Ramalingam

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19658185%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

English

0 references

publication date

1 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19658185%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

number of pages

12

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19658185%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19658185%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19658185%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

5143-5154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19658185%20AND%20SRC:MED&resulttype=core&format=json

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Epidermal growth factor receptor inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Antiangiogenic therapy in nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Considerations for second-line therapy of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Proposal for the use of progression-free survival in unblinded randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

7 January 2021

Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

7 January 2021

Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

7 January 2021

Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

7 January 2021

Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

7 January 2021

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

7 January 2021

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24563

7 January 2021